一からわかる循環器腎臓病学

出版社： 文光堂
著者：
発行日： 2021-03-16
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784830619687
電子書籍版： 2021-03-16 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

5,500 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

5,500 円(税込)

購入する

商品紹介

超高齢社会となり慢性腎臓病（CKD）を合併する心血管疾患患者が増えている．近年の心腎症候群 cardiorenal syndrome（CRS）という概念の導入で，心臓と腎臓の密接な連関は日常診療においても重要な領域となっているが臨床エビデンスは少ない．本書は今まであまり触れられてこなかったCKD合併心血管疾患の疫学，病態，機序，診断，リスク層別化，治療について，執筆陣のエキスパートオピニオンを盛り込み，現時点でのスタンダードを確立することを目指した一冊．

目次

  • 序　章
    　A　心腎連関（cardio-renal connection）は何が問題なのか？

    Ｉ　心不全と腎不全の関係を考える－cardio-renal syndrome
    　A　cardiorenal syndrome （CRS）とは？
    　B　CRS type1－急性心不全とAKI
    　　1　なぜAKIが起きるか？
    　　2　AKIの診断
    　　3　心筋傷害の診断
    　　4　急性心不全患者の利尿をどうするか？
    　　5　利尿以外の心不全薬物治療をどうするか？
    　C　CRS type2―慢性心不全とCKD
    　　1　CKD合併による慢性心不全患者の予後
    　　2　慢性心不全患者で腎機能が悪化する機序は？
    　　3　塩分制限と水分制限
    　　4　慢性期の利尿薬投与
    　　5　HFrEF患者の薬物療法
    　　6　HFpEF患者の薬物療法
    　　7　SGLT2阻害薬の心腎保護効果
    　　8　腎機能悪化を防ぐために回避すべき薬剤
    　　9　デバイス治療の有効性
    　　10　再入院予防のために注意すべきこと
    　　11　心臓リハビリと腎臓リハビリ
    　　12　左室補助循環と腎機能
    　　13　CKD合併症の治療
    　　14　末期心不全患者の緩和ケア
    　　［Meet the expert］Fontan術後のCKD
    　D　CRS type3　急性腎障害による心不全
    　E　CRS type4　CKDの結果生じる慢性心不全とは？
    　F　CRS type5　二次性の心臓と腎臓障害

    II　腎不全と心血管イベントの関係を考える
    　A　疫学と機序
    　　1　CKDで増加する冠動脈疾患
    　　2　CKDと動脈硬化－その機序
    　　3　尿毒素と動脈硬化
    　B　診　断
    　　1　CKD合併冠動脈疾患患者の特徴
    　　2　CKD合併急性心筋梗塞の特徴
    　　［Topics］CKD患者だけでもトロポニンが上昇する？
    　　3　冠動脈疾患の診断
    　　［Topics］CKDと冠動脈石灰化
    　　［Meet the expert］造影剤腎症をどのように予防するか
    　C　治　療
    　　1　薬物治療
    　　2　血行再建の適応と選択
    　D　末梢動脈疾患
    　　1　疫学と診断
    　　2　治　療

    III　腎不全と不整脈を考える
    　A　心房細動
    　　1　疫学と機序
    　　2　病　態
    　　3　抗凝固療法
    　　4　カテーテルアブレーション
    　B　CKDと突然死

    IV　透析と腎移植の心血管疾患への影響を考える
    　A　透析患者
    　　1　透析と心血管疾患－疫学
    　　2　透析の心血管系への影響
    　　3　冠動脈疾患の特徴と診断
    　　4　冠動脈疾患の治療－薬物治療と血行再建
    　　5　心不全の診断
    　　6　心不全の治療
    　B　腎移植患者
    　　1　動脈硬化への影響
    　　2　心不全への影響

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序章

P.4 掲載の参考文献
1) Keith, DS et al : Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164 : 659-663, 2004
 
2) Rangaswami, J et al : Cardiorenal Syndrome : Classification, Pathophysiology, Diagnosis, and Treatment Strategies : A Scientific Statement From the American Heart Association. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. Circulation 139 : e840-e878, 2019
PubMed
3) Ahmad, T et al : Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. Circulation 137 : 2016-2028, 2018
 
4) Yokoyama, S et al : Time Course Changes in Urinary Angiotensinogen and Circulating N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Acute Heart Failure. Intern Med 59 : 2839-2847, 2020.
 
5) Ronco, C et al : A Call to Action to Develop Integrated Curricula in Cardiorenal Medicine. Rev Cardiovasc Med 18 : 93-99, 2017
 

I 心不全と腎不全の関係を考える - cardio - renal syndrome

P.7 掲載の参考文献
1) Ronco, C et al : Cardiorenal syndromes : an executive summary from the consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 165 : 54-67, 2010
PubMed
2) Heywood, JT et al : High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure : a report from the ADHERE database. J Card Fail 13 : 422-430, 2007
PubMed
P.11 掲載の参考文献
1) Firth, JD et al : Raised venous pressure : a direct cause of renal sodium retention in oedema? Lancet 1 : 1033-1035, 1988
 
2) Colombo, PC et al : Inflammatory activation : cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 17 : 177-190, 2012
PubMed
3) Colombo, PC et al : Endothelial cell activation in patients with decompensated heart failure. Circulation 111 : 58-62, 2005
PubMed
4) Cheatham, ML et al : Abdominal perfusion pressure : a superior parameter in the assessment of intra-abdominal hypertension. J Trauma 49 : 621-626, 2000
PubMed
5) Mullens, W et al : Elevated intra-abdominal pressure in acute decompensated heart failure : A potential contributor to worsening renal function? J Am Coll Cardiol 51 : 300-306, 2008
PubMed
6) Ljungman, S et al : Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs 39 (Suppl 4) : 10-21, 1990
 
7) Mullens, W et al : Evaluation of kidney function throughout the heart failure trajectory-a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22 : 584-603, 2020
 
8) House, AA et al : Heart failure in chronic kidney disease : conclusions from a Kidney Disease : Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95 : 1304-1317, 2019
PubMed
P.14 掲載の参考文献
1) Ronco, C et al : Cardiorenal syndrome. J Am Coll Cardiol 52 : 1527-1539, 2008
PubMed
2) Metha RL, et al. Acute Kidney Injury Network : report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007 ; 11 : R31.
 
3) Testani, JM et al : Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122 : 265-272, 2010
PubMed
4) Metra, M et al : Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5 : 54-62, 2012
PubMed
5) Aronson, D et al : The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J Card Fail 16 : 541-547, 2010
PubMed
6) Sai, S et al : Clinical impacts of changes of renal function during hospitalization depend on grades of renal dysfunction in acute decompensated heart failure. Heart Vessels 35 : 509-520, 2020
PubMed
7) Murray, PT et al : Potential use of biomarkers in acute kidney injury : report and summary of recommendations from the 10th Acute Dialysis Quality Initiative consensus conference. Kidney Int 85 : 513-521, 2014
PubMed
8) Alge, JL et al : Biomarkers of AKI : a review of mechanistic relevance and potential therapeutic implications. Clin J Am Soc Nephrol 10 : 147-155, 2015
 
9) AKI (急性腎障害) 診療ガイドライン作成委員会 (編) : AKI (急性腎障害) 診療ガイドライン 2016. 日本腎臓学会誌 59 : 419-533, 2017
 
10) Nakada, Y et al : Prognostic value of urinary neutrophil gelatinase-associated lipocalin on the first day of admission for adverse events in patients with acute decompensated heart failure. J Am Heart Assoc 6 : e004582, 2017
PubMed
11) Shirakabe, A et al : Clinical usefulness of urinary liver fatty acid binding protein excretion for predicting acute kidney injury during the first 7 days and the short-term prognosis in acute heart failure patients with non-chronic kidney disease. Cardiorenal Med 7 : 301-315, 2017
PubMed
12) Iida, N et al : Clinical Implications of Intrarenal Hemodynamic Evaluation by Doppler Ultrasonography in Heart Failure. JACC Heart Fail 4 : 674-678, 2016
PubMed
13) Chiba, H et al : Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion. Hypertens Res 42 : 319-328, 2019
PubMed
P.17 掲載の参考文献
1) Maisel, A et al : Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44 : 1328-1333, 2004
PubMed
2) Fonarow, GC et al ; ADHERE Scientific Advisory Committee and Investigators : Admission-B-type-natriuretic-peptide-levels-and-in-hospital-mortality-in-acute decompensated heart failure. J Am Coll Cardiol 49 : 1943-1950, 2007
PubMed
3) Peacock, WF 4th et al : Cardiac troponin and outcome in acute heart failure. N Engl J Med 358 : 2117-2126, 2008
PubMed
4) Sakhuja, R et al : Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure. Clin Chem 53 : 412-420, 2007
PubMed
5) Zoccali, C et al : Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 12 : 1508-1515, 2001
PubMed
P.20 掲載の参考文献
1) Ambrosy, AP et al : Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction : findings from the EVEREST trial. Eur Heart J 34 : 835-843, 2013
PubMed
2) Valente, MA et al : Diuretic response in acute heart failure : clinical characteristics and prognostic significance. Eur Heart J 35 : 1284-1293, 2014
PubMed
3) Inomata, T et al : Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment-Results From the K-STAR Study. Circ J 82 : 159-167, 2017
 
4) Mullens, W et al : Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53 : 589-596, 2009
PubMed
5) Bart, BA et al : Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367 : 2296-2304, 2012
PubMed
6) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). http://www.j-circ.or.jp/cms/wpcontent/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
P.22 掲載の参考文献
1) Metra, M et al : Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail 5 : 54-62, 2012
PubMed
2) Chen, HH et al : Low Dose Dopamine or Low Dose Nesiritide in Acute Heart Failure with Renal Dysfunction : The ROSE Acute Heart Failure Randomized Trial. JAMA 310 : 2533-2543, 2013
 
3) Fonarow, GC et al : Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure : findings from the OPTIMIZE-HF program. J Am Coll Cardiol 52 : 190-199, 2008.
PubMed
4) Oliveros, E et al : Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists During Hospitalizations for Acute Heart Failure. Cardiorenal Med 10 : 69-84, 2020
PubMed
5) Albaghdadi, M et al : Mineralocorticoid receptor antagonism : therapeutic potential in acute heart failure syndromes. Eur Heart J 32 : 2626-2633, 2011
PubMed
P.26 掲載の参考文献
1) Damman, K et al : Renal impairment, worsening renal function, and outcome in patients with heart failure : an updated meta-analysis. Eur Heart J 35 : 455-469, 2014
PubMed
2) Hillege, HL et al : Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 : 203-210, 2000
PubMed
3) Hillege, HL et al : Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113 : 671-678, 2006
 
4) Jackson, CE et al : Albuminuria in chronic heart failure : prevalence and prognostic importance. Lancet 374 : 543-550, 2009
PubMed
5) Miura, M et al : Prognostic impact of subclinical micro-albuminuria in patients with chronic heart failure. Circ J 78 : 2890-2898, 2014
 
6) Bansal, N et al : Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease. J Am Coll Cardiol 73 : 2691-2700, 2019.
PubMed
7) Schefold, JC et al : Heart failure and kidney dysfunction : epidemiology, mechanisms and management. Nat Rev Nephrol 12 : 610-623, 2016
PubMed
P.30 掲載の参考文献
1) Cruz, DN et al : Pathophysiology of cardiorenal syndrome type 2 in stable chronic heart failure : workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 182 : 117-136, 2013
PubMed
2) Damman, K et al : Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular diseasee. J Am Coll Cardiol 53 : 582-588, 2009
 
3) Mullens, W et al : Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53 : 589-596, 2009
PubMed
4) Ellison, DH et al : Diuretic Treatment in Heart Failure. N Engl J Med 377 : 1964-1975, 2017
PubMed
5) Silverberg, DS et al : The cardio renal anemia syndrome : correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol 60 Suppl 1 : S93-S102, 2003
 
6) McFarlane, SI et al : Role of the natriuretic peptide system in cardiorenal protection. Arch Intern Med 163 : 2696-2704, 2003
PubMed
P.32 掲載の参考文献
1) Tsutsui, H et al : JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure-Digest Version. Circ J 83 : 2084-2184, 2019
 
2) HFSA guidelines for the management of patients with heart failure due to left ventricular systolic dysfunction--phar-macological approaches. Congest Heart Fail 6 : 11-39, 2000
 
3) Yancy, CW et al : 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure : A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136 : 137-161, 2017
 
4) Ponikowski, P et al : 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37 : 2129-2200, 2016
 
P.35 掲載の参考文献
1) Ahmed, A et al : Heart failure, chronic diuretic use, and increase in mortality and hospitalization : an observational study using propensity score methods. Eur Heart J 27 : 1431-1439, 2006
PubMed
2) Zelniker, TA et al : Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors : JACC state-of-the-art review. J Am Coll Cardiol 75 : 435-447, 2020
PubMed
3) Zinman, B et al ; for the EMPA-REG OUTCOME Investigators : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
4) McMurray, JJV et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
5) Konstam, MA et al : Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST Outcome Trial. JAMA 297 : 1319-1331, 2007
PubMed
6) Imamura, T et al : Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 78 : 2240-2249, 2014
PubMed
P.39 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wpcontent/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年9月閲覧)
 
2) Badve, SV et al : Effects of beta-adrenergic antagonists in patients with chronic kidney disease : a systematic review and meta-analysis. J Am Coll Cardiol 58 : 1152-1161, 2011
PubMed
3) Greene, SJ et al : Medical Therapy for Heart Failure With Reduced Ejection Fraction : The CHAMP-HF Registry. J Am Coll Cardiol 72 : 351-366, 2018
PubMed
4) Damman, KJ et al : Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure. JACC Heart Fail 6 : 489-498, 2018
 
5) McMurray, JJV et al : Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
P.41 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wpcontent/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年9月閲覧)
 
2) Yancy, CW et al : 2013 ACCF/AHA Guideline for the Management of Heart Failure. Circulation 128 : 240-327, 2013
 
3) Brouwers, FP et al : Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort : 11-year follow-up of PREVEND. Eur Heart J 34 : 1424-1431, 2013
 
4) Nishio, M et al : Difference of clinical characteristics between hypertensive patients with and without diastolic heart failure : role of diastolic dysfunction and renal insufficiency. Hypertens Res 31 : 1865-1872, 2008
 
5) Masuyama, T et al : Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J 76 : 833-842, 2012
PubMed
6) Imamura, T et al : Tolvaptan Improves the Long-Term Prognosis in Patients With Congestive Heart Failure With Preserved Ejection Fraction as Well as in Those With Reduced Ejection Fraction. Int Heart J 57 : 600-606, 2016
 
7) Beldhuis, IE et al : Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney Disease. JACC Heart Fail 7 : 25-32, 2019
PubMed
8) Solomon, SD et al ; PARAGON-HF Investigators and Committees : Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 381 : 1609-1620, 2019
PubMed
P.45 掲載の参考文献
1) Zinman, B et al : Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 : 2117-2128, 2015
PubMed
2) Neal, B et al : Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 377 : 644-657, 2017
PubMed
3) Wiviott, SD et al : Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 380 : 347-357, 2019
PubMed
4) Perkovic, V et al : Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 380 : 2295-2306, 2019
PubMed
5) McMurray, JJV et al : Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
6) Cherney, DZI et al : Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 : 587-597, 2014
 
P.47 掲載の参考文献
1) Carubelli,V et al : Negotiating renal dysfunction when treating patients with heart failure. Expert Rev Cardiovasc Ther 16 : 113-122, 2018
PubMed
2) Rao, VS et al : Compensatory distal reabsorption drives diuretic resistance in human heart failure. J Am Soc Nephrol 28 : 3414-3424, 2017
PubMed
3) Kohn, SM et al : Chloride ion in intensive care medicine. Crit Care Med 20 : 227-240,1992
 
4) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2018, 東京医学社, 東京, 2018
 
5) 薬剤性腎障害の診療ガイドライン作成委員会 : 薬剤性腎障害の診療ガイドライン 2016. 日腎会誌 58 : 477-555, 2016
 
P.49 掲載の参考文献
1) Hager, CS et al : Effect of renal function on survival after implantable cardioverter defibrillator placement. Am J Cardiol 106 : 1297-1300, 2010
PubMed
2) Bansal, N et al : Long-term Outcomes Associated With Implantable Cardioverter Defibrillator in Adults With Chronic Kidney Disease. JAMA Intern Med 178 : 390-398, 2018
PubMed
3) Jukema, JW et al : Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation 139 : 2628-2638, 2019
PubMed
4) Bazoukis, G et al : Impact of baseline renal function on all-cause mortality in patients who underwent cardiac resynchronization therapy : A systematic review and meta-analysis. J Arrhythm 33 : 417-423, 2017
PubMed
5) Kpaeyeh, JA Jr et al : Impact of Renal Function on Survival After Cardiac Resynchronization Therapy. Am J Cardiol 120 : 262-266, 2017
PubMed
P.51 掲載の参考文献
1) Ichiki, T et al : Post-transcriptional modification of pro-BNP in heart failure : is glycosylation and circulating furin key for cardiovascular homeostasis? Eur Heart J 35 : 3001-3003, 2014
PubMed
2) Takahama, H et al : Change in the NT-proBNP/Mature BNP Molar Ratio Precedes Worsening Renal Function in Patients With Acute Heart Failure : A Novel Predictor Candidate for Cardiorenal Syndrome. J Am Heart Assoc 8 : e011468, 2019
PubMed
3) Damman, K et al : Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53 : 582-588, 2009
 
4) Mullens, W et al : Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53 : 589-596, 2009
PubMed
5) Badve, SV et al : Effects of beta-adrenergic antagonists in patients with chronic kidney disease : a systematic review 心腎症候群における悪循環への対策 and meta-analysis. J Am Coll Cardiol 58 : 1152-1161, 2011
 
P.54 掲載の参考文献
1) 上月正博 : 腎臓リハビリテーション, 第2版, 上月正博 (編著), 医葉薬出版, 東京, 2018
 
2) 日本腎臓リハビリテーション学会 (編) : 腎臓リハビリテーションガイドライン, 南江堂, 東京, 2018
 
3) Scrutinio, D et al ; MECKI Score Research Group : Renal function and peak exercise oxygen consumption in chronic heart failure with reduced left ventricular ejection fraction. Circ J 79 : 583-591, 2015
 
4) Takaya, Y et al : Impact of cardiac rehabilitation on renal function in patients with and without chronic kidney disease after acute myocardial infarction. Circ J 78 : 377-384, 2014
PubMed
5) Sato, T et al : Association between physical activity and change in renal function in patients after acute myocardial infarction. PLoS One14 : e0212100, 2019
PubMed
6) 日本腎臓リハビリテーション学会・日本心臓リハビリテーション学会からの共同ステートメント : 骨格筋量低値患者または運動療法実施患者における推定糸球体濾過量 (eGFR) による腎機能評価について. 日本腎臓リハビリテーション学会ホームページ https://jsrr.jimdofree.com/ 学会関連資料/心臓リハビリテーション学会との共同ステートメント (2020年12月閲覧)
 
P.57 掲載の参考文献
1) Imamura, T et al : Preoperative levels of bilirubin or creatinine adjusted by age can predict their reversibility after implantation of left ventricular assist device. Circ J 77 : 96-104, 2013
PubMed
P.59 掲載の参考文献
1) Moe, S et al : Definition, evaluation, and classification of renal osteodystrophy : a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int 69 : 1945-1953, 2006
PubMed
2) Tentori, F et al : Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH : the Dialysis Outcomes and Practice Patterns Study (DOPPS). 52 : 519-530, 2008
PubMed
3) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2009, 東京医学社, 東京, 2009
 
4) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2018, 東京医学社, 東京, 2018
 
5) 南学正臣 : 慢性腎臓病と各種疾患 腎性貧血. 日本内科学会誌 101 : 1318-1324, 2012
 
6) Palazzuoli, A et al : Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am Heart J 152 : 1096, 2006
PubMed
7) 濱野高行 : 腎性貧血. 日本腎臓学会誌 62 : 34-40, 2020
 
P.62 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wpcontent/uplods/2017/06/JCS2017_tsutsui_h.pdf (2020年9月閲覧)
 
2) 日本緩和医療学会 : WHO (世界保健機関) による緩和ケアの定義 (2002). http://www.jspm.ne.jp/proposal/proposal.html (2020年9月閲覧)
 
3) 日本医師会 : 終末期医療アドバンス・ケア・プランニング (ACP) から考える. http://www.med.or.jp/doctor/rinri/i_rinri/006612.html (2020年9月閲覧)
 
4) Allen, LA et al : Decision making in advanced heart failure : a scientific statement from the American Heart Association. Circulation 125 : 1928-1952, 2012
PubMed
5) 厚生労働省 : 人生の最終段階における医療・ケアの決定プロセスに関するガイドライン, 平成30年3月改訂版. https://www.mhlw.go.jp/file/06-Seisakujouhou-10800000-Iseikyoku/0000197721.pdf (2021年1月閲覧)
 
6) 透析の開始と継続に関する意思決定プロセスについての提言作成委員会 : 透析の開始と継続に関する意思決定プロセスについての提言. 透析会誌 53 : 173-217, 2020
 
P.65 掲載の参考文献
1) 杜徳尚 : Fontan術後の抗凝固療法をどのようにしたらよいでしょうか?. 血栓を制するものは心臓を制す! 血栓循環器学 Q&A, 伊藤浩 (編), 文光堂, 東京, 61, 2019
 
2) Dimopoulos, K et al : Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation 117 : 2320-2328, 2008
PubMed
3) Sharma, S et al : Assessment of Kidney Function in Survivors Following Fontan Palliation. Congenit Heart Dis 11 : 630-636, 2016.
PubMed
4) Perloff, JK et al : Pathogenesis of the glomerular abnormality in cyanotic congenital heart disease. Am J Cardiol 86 : 1198-1204, 2000
PubMed
5) Wilson, TG et al : Australian and New Zealand Fontan Registry. Hepatic and renal end-organ damage in the Fontan circulation : A report from the Australian and New Zealand Fontan Registry. Int J Cardiol 273 : 100-107, 2018
PubMed
6) Welke, KF et al : Renal complications associated with the treatment of patients with congenital cardiac disease : consensus definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease. Cardiol Young 18 Suppl 2 : 222-225, 2008
PubMed
7) Damman, K et al : Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 53 : 582-588, 2009
 
8) Opotowsky, AR et al : Estimated glomerular filtration rate and urine biomarkers in patients with single-ventricle Fontan circulation. Heart 103 : 434-442, 2017
PubMed
9) Ohuchi, H et al : Renal resistive index reflects Fontan pathophysiology and predicts mortality. Heart 103 : 1631-1637, 2017
PubMed
P.68 掲載の参考文献
1) Grams, ME et al : The distant organ effects of acute kidney injury. Kidney Int 81 : 942-948, 2012
PubMed
2) Kelly, KJ : Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol 14 : 1549-1558, 2003
PubMed
3) Prabhu, SD : Cytokine-induced modulation of cardiac function. Circ Res 95 : 1140-1153, 2004
PubMed
4) James, MT et al : Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 123 : 409-416, 2011
PubMed
P.71 掲載の参考文献
1) Schiffrin, El et al : Chronic kidney disease : effect on the cardiovasucular system. Circulation 116 : 85-97, 2007
 
2) Clementi, A et al : Cardiorenal syndrome type 4 : a review. Cardiorenal Med 3 : 63-70, 2013
PubMed
3) Kato, MF et al : Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension : Role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens 26 : 1669-1676, 2008
PubMed
4) Lekawanvijit, S : Cardiotoxicity of Uremic Toxins : A Driver of Cardiorenal Syndrome. Toxins (Basel) 10 : 352, 2018
 
5) de Albuquerque Suassuna, PG et al : Uremic Cardiomyopathy : A New Piece in the Chronic Kidney Disease-Mineral and Bone Disorder Puzzle. Front Med (Lausanne) 5 : 206, 2018
PubMed
6) Kimoto, E et al : Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease. J Am Soc Nephrol 17 : 2245-2252, 2006
PubMed
7) Wali, RK et al : Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 45 : 1051-1060, 2005
PubMed
8) Hu, MC et al : Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease pro-gression and uremic cardiomyopathy. Kidney Int 91 : 1104-1114, 2017
 
P.74 掲載の参考文献
1) Rangaswami, J et al : Cardiorenal Syndrome : Classification, Pathophysiology, Diagnosis, and Treatment Strategies. A Scientific Statement From the American Heart Association. Circulation 39 : e840-e878, 2019
 
2) Ronco C, et al : Cardiorenal Syndrome : An Overview. Adv Chronic Kidne Dis 25 : 382-390, 2018
 
3) Ravindra, L et al : Cardiorenal Syndrome Type 5 : Clinical Presentation, Pathophysiology and Management Strategies from the Eleventh Consensus Conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol 182 : 174-194, 2013
 
4) Kotecha, A et al : Cardiorenal syndrome in sepsis : A narrative review. J Crit Care 43 : 122-127, 2018
PubMed
5) 安東由喜雄 (監修), 植田光晴 (編) : 最新アミロイドーシスのすべて-診療ガイドライン 2017とQ&A, 医歯薬出版, 東京, 2017
 
6) 日本循環器学会 : 2020年版 心アミロイドーシス診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2020_Kitaoka.pdf (2020年9月閲覧)
 

II 腎不全と心血管イベントの関係を考える

P.78 掲載の参考文献
1) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2012. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
 
2) Murphy, D et al : Trends in Prevalence of Chronic Kidney Disease in the United States. Ann Intern Med 165 : 473-481, 2016
PubMed
3) Imai, E et al : [Prevalence and perspectives of CKD in Japan]. Nihon Jinzo Gakkai shi 48 : 703-710, 2006
PubMed
4) Matsushita, K et al : Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts : a collaborative meta-analysis. Lancet 375 : 2073-2081, 2010
PubMed
5) Shlipak, MG et al : Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 369 : 932-943, 2013
PubMed
P.82 掲載の参考文献
1) Kashihara, N et al : Oxidative stress in diabetic nephropathy. Curr Med Chem 17 : 4256-4269, 2010
PubMed
2) Li, JM et al : ROS generation by nonphagocytic NADPH oxidase : potential relevance in diabetic nephropathy. J Am Soc Nephrol 14 : S221-226, 2003
PubMed
3) 神戸茂雄ほか : 血管内皮障害, NO. 動脈硬化診療のすべて, 日本医師会 (編), 磯部光章ほか (監), 南江堂, 東京, S60-61, 2019
 
4) 柏原直樹ほか : 酸化ストレス処理機能と腎障害. 日本内科学会雑誌 106 : 1473-1480, 2017
 
5) 庄司哲雄 : CKDと脂質異常症-成因と治療. Medical Practice 36 : 85-90, 2019
Medical*Online
6) Tonelli, M et al : Association Between LDL-C and Risk of Myocardial Infarction in CKD. J Am Soc Nephrol 24 : 979-986, 2013
 
7) Tumur, Z et al : Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells. Am J Nephrol 29 : 551-557, 2009
PubMed
8) Tumur, Z et al : Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol 31 : 435-441, 2010
PubMed
9) 大野洋一 : RASとCKDと血栓性疾患の発症制御. Angiotensin Research 11 : 23-28, 2014
Medical*Online
P.85 掲載の参考文献
1) Schlesinger, S et al : Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes : A Systematic Review and Meta-Analysis of Prospective Studies. PLoS One 11 : e0165811, 2016
PubMed
2) Schiattarella, GG et al : Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker : a systematic review and dose-response meta-analysis. Eur Heart J 38 : 2948-2956, 2017
PubMed
3) Arnlov, J et al : Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 8 : 781-786, 2013
PubMed
4) Liabeuf, S et al : Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25 : 1183-1191, 2010
 
5) Watanabe, I et al : Prognostic Utility of Indoxyl Sulfate for Patients with Acute Coronary Syndrome. J Atheroscler Thromb 26 : 64-71, 2019
PubMed
P.88 掲載の参考文献
1) Kidney Disease Improving Global Outcomes (KDIGO) : Clinical practice guideline for acute kidney injury. Kidney Int Suppl 2 : 1-138, 2012
 
2) Chertow, GM et al : "Renalism" : inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency. J Am Soc Nephrol 15 : 2462-2468, 2004
PubMed
3) Sarnak, MJ et al : Chronic Kidney Disease and Coronary Artery Disease : JACC State-of-the-Art Review. J Am Coll Cardiol 74 : 1823-1838, 2019
PubMed
4) Spertus, JA et al : Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. N Engl J Med 382 : 1408-1419, 2020
 
5) Spertus, JA et al : Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. N Engl J Med 382 : 1619-1628, 2020
 
6) Deguchi, Y et al : Trajectory of renal function change and kidney injury after percutaneous coronary intervention in patients with stable coronary artery disease. Heart Vessels Sep 15, 2020
 
7) Anavekar, NS et al : Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 : 1285-1295, 2004
PubMed
P.92 掲載の参考文献
1) Fox, CS et al : Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non-ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease. Circulation 121 : 357-365, 2010
PubMed
2) Navarro, MA et al : Chronic Kidney Disease and Health Status Outcomes Following Acute Myocardial Infarction. J Am Heart Assoc 5 : e002772, 2016
PubMed
3) Shroff, GR et al : Renal failure and acute myocardial infarction : clinical characteristics in patients with advanced chronic kidney disease, on dialysis, and without chronic kidney disease : a collaborative project of the United States Renal Data System/National Institutes of Health and the National Registry of Myocardial Infarction. Am Heart J 163 : 399-406, 2012
 
4) Szummer, K et al : Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome : data from the SWEDEHEART register. J Intern Med 268 : 40-49, 2010
 
5) Gunsolus, I et al : Renal Dysfunction Influences the Diagnostic and Prognostic Performance of High-Sensitivity Cardiac Troponin I. J Am Soc Nephrol 29 : 636-643, 2018
PubMed
P.94 掲載の参考文献
1) Mariathas, M et al : True 99th centile of high sensitivity cardiac troponin for hospital patients : prospective, observational cohort study. Br Med J 364 : 1729, 2019
 
2) Twerenbold, R et al : Optimal cutoff levels of more sensitive cardiac troponin assays for the early diagnosis of myocardial infarction in patients with renal dysfunction. Circulation 131 : 2041-2050, 2015
PubMed
3) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://j-circ.or.jp/cms/wpcontent/uploads/2017/06/JCS2017_tsutsui_h.pdf (2020年10月閲覧)
 
4) Miller-Hodges, E et al : High-sensitivity cardiac troponin and the risk stratification of patients with renal impairment presenting with suspected acute coronary syndrome. Circulation 137 : 425-435, 2018
PubMed
P.99 掲載の参考文献
1) 日本循環器学会 : 慢性冠動脈疾患診断ガイドライン (2018年改訂版). http://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_yamagishi_tamaki.pdf (2020年10月閲覧)
 
2) Winther, S et al : Diagnostic Performance of Coronary CT Angiography and Myocardial Perfusion Imaging in Kidney Transplantation Candidates. JACC Cardiovasc Imaging 8 : 553-562, 2015
PubMed
3) 日本腎臓学会・日本医学放射線学会・日本循環器学会 (共同編) : 腎障害患者におけるヨード造影剤使用に関するガイドライン 2018. 日腎会誌 61 : 933-1081, 2019
 
4) Kato, S et al : Assessment of coronary artery disease using magnetic resonance coronary angiography : a national multicenter trial. J Am Coll Cardiol 56 : 983-991, 2010
PubMed
5) Nakamura, S et al : Prognostic study of cardiac events in Japanese patients with chronic kidney disease using ECG-gated myocardial Perfusion imaging : Final 3-year report of the J-ACCESS 3 study. J Nucl Med 26 : 431-440, 2019
 
6) Amann, K et al : Q Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 17 : 2112-2119, 2006
 
7) Tsuda, N et al : Quantification of myocardial perfusion reserve using dynamic SPECT images of patients with chronic kidney disease. J Cardiol 71 : 174-180, 2018
PubMed
P.101 掲載の参考文献
1) Budoff, MJ et al : Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis 58 : 519-526, 2011
PubMed
2) Chen, J et al : Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. JAMA Cardiol 2 : 635-643, 2017
PubMed
3) Shimoyama, Y et al : Coronary artery calcification score is associated with mortality in Japanese hemodialysis patients. J Ren Nutr 22 : 139-142, 2012
PubMed
P.104 掲載の参考文献
1) 日本腎臓学会・日本医学放射線学会・日本循環器学会 (共同編) : 腎障害患者におけるヨード造影剤使用に関するガイドライン 2018. 日腎会誌 61 : 933-1081, 2019
 
2) Judd, E et al : Diagnosis and Clinical Evaluation of Acute Kidney Injury. Comprehensive Clinical Nephrology, 6th edition, Johnson, RJ et al (eds), Elsevier, Amsterdam, 810-819. e1, 2018
 
3) ESUR (European Society of Urogenital Radiology) Guidelines on Contrast Agents 10.0. http://www.esur.org/fileadmin/content/2019/ESUR_Guidelines_10.0_Final_Version.pdf
 
4) 笠原正登ほか : 造影剤腎症の病態と対策. 月刊循環器 Circulation 3 : 97-104, 2013
 
5) Saito, Y et al : Proteinuria and Reduced Estimated Glomerular Filtration Rate Are Independent Risk Factors for Contrast-Induced Nephropathy After Cardiac Catheterization. Circ J 79 : 1624-1630, 2015
PubMed
P.108 掲載の参考文献
1) ACCORD Study Group : Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362 : 1575-1585, 2010
 
2) Imai, E et al : Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy : a post hoc analysis (ORIENT-blood pressure). Nephrol Dial Transplant 31 : 447-454, 2016
PubMed
3) SPRINT Research Group : A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373 : 2103-2116, 2015
 
4) Hirayama, A et al : Blood Pressure, Proteinuria, and Renal Function Decline : Associations in a Large Community-Based Population. Am J Hypertens 28 : 1150-1156, 2015
 
5) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2018, 東京医学社, 東京, 2018
 
6) Xie, X et al : Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD : A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 67 : 728-741, 2016
PubMed
7) Nistor, I et al : Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis : a systematic review and meta-analysis. Nephrol Dial Transplant 33 : 12-22, 2018
 
8) Schmidt, M et al : Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks : cohort study. BMJ 356 : j791, 2017
PubMed
9) Clase, CM et al : Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. Kidney Int 91 : 683-690, 2017
 
10) Wali, RK et al : Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease : a meta-analysis of randomized trials. Circ Heart Fail 4 : 18-26, 2011
PubMed
11) Badve, SV et al : Effects of beta-adrenergic antagonists in patients with chronic kidney disease : a systematic review and meta-analysis. J Am Coll Cardiol 58 : 1152-1161, 2011
PubMed
12) Baigent, C et al : The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial. Lancet 377 : 2181-2192, 2011
PubMed
13) Natsuaki, M et al : Renal function and effect of statin therapy on cardiovascular outcomes in patients undergoing coronary revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol 110 : 1568-1577, 2012
PubMed
14) Charytan, DM et al : Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol 73 : 2961-2970, 2019
 
15) Tunon, J et al : Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome : prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J 41 : 4114-4123, 2020
PubMed
16) Su, X et al : Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease : a systematic review and meta-analysis. BMC Nephrol 20 : 309, 2019
PubMed
P.113 掲載の参考文献
1) Sakai, K et al : Impact of intravascular ultrasound-guided minimum-contrast coronary intervention on 1-year clinical outcomes in patients with stage 4 or 5 advanced chronic kidney disease. Cardiovasc Interv Ther 34 : 234-241, 2019
PubMed
2) Ikari, Y et al : Sirolimus eluting coronary stent implantation in patients on maintenance hemodialysis : the OUCH study (outcome of cypher stent inhemodialysis patients). Circ J 76 : 1856-1863, 2012
PubMed
3) Kozuma, K et al : Clinical and angiographic outcomes of paclitaxel-eluting coronary stent implantation in hemodialysis patients : A prospective multicenter registry : The OUCH-TL study (outcome in hemodialysis of TAXUS Liberte). J Cardiol 66 : 502-508, 2015
PubMed
4) Ikari, Y et al : Usefulness of Everolimus-Eluting Coronary Stent Implantation in Patients on Maintenance Hemodialysis. Am J Cardiol 116 : 872-876, 2015
PubMed
5) Spertus, JA et al : Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. N Engl J Med 382 : 1619-1628, 2020
 
6) 日本循環器学会/日本心臓血管外科学会 : 安定冠動脈疾患の血行再建ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_nakamura_yaku.pdf (2020年12月閲覧)
 
P.117 掲載の参考文献
1) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン Clinical Guidelines for the Evaluation and the Treatment of Cardiovascular Complications in Hemodialysis Patients. 透析会誌 44 : 337-425, 2011
 
2) Yamazaki, T et al : Prevalence, Awareness and Treatment of Cardiovascular Risk Factors in Patients at High Risk of Atherothrombosis in Japan. Circ J 71 : 995-1003, 2007
PubMed
3) Hirsch, AT et al : ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) : Executive Summary A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol 47 : 1239-1312, 2006
 
4) Orimoto, Y et al : The prognosis of patients on hemodialysis with foot lesions. J Vasc Surg 58 : 1291-1299, 2013
PubMed
5) TASC II Working Group (日本脈管学会訳) : 下肢閉塞性動脈硬化症の診断・治療指針 II. メディカルトリビューン, 1-109, 2007
 
6) 日本循環器学会 : 末梢閉塞性動脈疾患の治療ガイドライン (2015年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2015_miyata_h.pdf (2020年10月閲覧)
 
P.122 掲載の参考文献
1) 日本循環器学会 : 末梢閉塞性動脈疾患の治療ガイドライン (2015年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2015_miyata_h.pdf (2020年12月閲覧)
 
2) Norgren, L et al : Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45 Suppl 1 : S5-67, 2007
 
3) Soga, Y et al ; REAL-AI investigators : Contemporary outcomes after endovascular treatment for aorto-iliac artery disease. Circ J 76 : 2697-2704, 2012
PubMed
4) Iida, O et al : Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment : retrospective multicenter analysis. J Endovasc Ther 18 : 753-761, 2011
PubMed
5) Ohki, T et al : Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. J Vasc Surg 66 : 130-142, 2017
PubMed
6) Iida, O et al ; MDT-2113 SFA Japan Investigators : Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries : One-Year Results of the MDT-2113 SFA Japan Randomized Trial. J Endovasc Ther 25 : 109-117, 2018
 
7) Aboyans, V et al ; ESC Scientific Document Group : 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS) : Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries Endorsed by : the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Euro Heart J 39 : 763-816, 2018
 
8) Iida, O et al : Three-Year Outcomes of Surgical Versus Endovascular Revascularization for Critical Limb Ischemia : The SPINACH Study 10 : e005531, 2017
PubMed
9) Iida, O et al : Endovascular treatment for infrainguinal vessels in patients with critical limb ischemia : OLIVE registry, a prospective, multicenter study in Japan with 12-month followup. Circ Cardiovasc Interv 6 : 68-76, 2013
 
10) Iida, O et al : Anatomical predictors of major adverse limb events after infrapopliteal angioplasty for patients with critical limb ischemia due to pure isolated infrapopliteal lesions. Eur J Vasc Endovasc Surg 44 : 318-324, 2012
PubMed

III 腎不全と不整脈を考える

P.126 掲載の参考文献
1) Kooiman, J et al : Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs. J Thromb Haemost 9 : 1652-1653, 2011
PubMed
2) Watanabe, H et al : Close bidirectional relationship between chronic kidney disease and atrial fibrillationthe Niigata preventive medicine study. Am Heart J 158 : 629-636, 2009
PubMed
3) Alonso, A et al : Chronic kidney disease is associated with the incidence of atrial fibrillation : the Atherosclerosis Risk In Communities (ARIC) study. Circulation 123 : 2946-2953, 2011
PubMed
4) Bansal, N et al : Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation 127 : 569-574, 2013
PubMed
5) Winkelmayer, WC et al : The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol 22 : 349-357, 2011
PubMed
6) Gupta, J et al : Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol 7 : 1938-1946, 2012
PubMed
7) Iravanian, S et al : The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 5 : S12-S17, 2008
PubMed
8) Severi, S et al : Alterations of atrial electrophysiology induced by electrolyte variations : combined computational and P-wave analysis. Europace 12 : 842-849, 2010
PubMed
9) Chan, CT et al : Determinants of cardiac autonomic dysfunction in ESRD. Clin J Am Soc Nephrol 5 : 1821-1827, 2010
PubMed
10) Schmidt, M et al : Renal dysfunction and atrial fibrillation recurrence following cardioversion. J Cardiovasc Electrophysiol 22 : 1092-1098, 2011
PubMed
11) Sairaku, A et al : Outcomes of ablation of paroxysmal atrial fibrillation in patients on chronic hemodialysis. J Cardiovasc Electrophysiol 23 : 1289-1294, 2012
PubMed
P.128 掲載の参考文献
1) Fauchier, L et al : Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012 : a nationwide database study. Open Heart 2 : e000290, 2015
PubMed
2) Violi, F et al : Relationship between low Ankle-Brachial Index and rapid renal function decline in patients with atrial fibrillation : a prospective multicentre cohort study. BMJ Open 5 : e008026, 2015
PubMed
3) 日本循環器学会/日本不整脈心電学会 : 2020年改訂版 不整脈薬物治療ガイドライン. http://www.j-circ.or.jp/cms/wpcontent/uploads/2020/01/JCS2020_Ono.pdf (2020年10月閲覧)
 
4) Abe, M et al : Relation of Stroke and Major Bleeding to Creatinine Clearance in Patients With Atrial Fibrillation (from the Fushimi AF Registry). AM J Cardiol 119 : 1229-1237, 2017
PubMed
5) Kodani E et al : Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation : a subanalysis of the J-RHYTHM Registry. Eur Heart J Qual Care Clin Outcomes 4 : 59-68, 2018
 
P.132 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会 : 2020年改訂版 不整脈薬物治療ガイドライン. https://www.j-circ.or.jp/cms/wpcontent/uploads/2020/01/JCS2020_Ono.pdf (2020年12月閲覧)
 
2) Nigwekar, SU et al : Calciphylaxis. N Engl J Med 378 : 1704-1714, 2018
PubMed
3) Yao, X et al : Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation. J Am Coll Cardiol 70 : 2621-3220, 2017
PubMed
4) Brodsky, SV et al : Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts : a report of 9 cases. Am J Kidney Dis 54 : 1121-1126, 2009
PubMed
5) Brodsky, S et al : Anticoagulant-Related Nephropathy. J Am Soc Nephrol 29 : 2787-2793, 2018
PubMed
6) Akao, M et al : Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban : J-ELD AF Registry subanalysis. Am Heart J 223 : 23-33, 2020
 
7) Kumar, S et al : Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation : JACC Review Topic of the Week. J Am Coll Cardiol 74 : 2204-2215, 2019
 
P.135 掲載の参考文献
1) Yanagisawa, S et al : Impaired renal function is associated with recurrence after cryoballoon catheter ablation for paroxysmal atrial fibrillation : A potential effect of non-pulmonary vein foci. J Cardiol 69 : 3-10, 2017
PubMed
2) Okawa, K et al : Improvement in renal and endothelial function after catheter ablation in patients with persistent atrial fibrillation. J Cardiol 76 : 610-617, 2020
PubMed
3) Park, JW et al : Five-Year Change in the Renal Function After Catheter Ablation of Atrial Fibrillation. J Am Heart Assoc 8 : e013204, 2019
PubMed
4) Bassand, JP et al : Two-year outcomes of patients with newly diagnosed atrial fibrillation : results from GARFIELD-AF. Eur Heart J 37 : 2882-2889, 2016
PubMed
5) Matsushita, K et al : Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts : a collaborative meta-analysis. Lancet 375 : 2073-2081, 2010
PubMed
P.138 掲載の参考文献
1) Shamseddin, MK et al : Sudden cardiac death in chronic kidney disease : epidemiology and prevention. Nat Rev Nephrol 7 : 145-154, 2011
PubMed
2) Poulikakos, D et al : Risk of sudden cardiac death in chronic kidney disease. J Cardiovasc Electrophysiol 23 : 222-231, 2014
 
3) Di Lullo, L et al : Sudden cardiac death and chronic kidney disease : from pathophysiology to treatment trategies. Int J Cardiol 217 : 16-27, 2016
 
4) Shimizu, W et al : Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus : the EMBODY trial. Caridiovasc Diabetology 19 : 148, 2020
 

IV 透析と腎移植の心血管疾患への影響を考える

P.141 掲載の参考文献
1) Weinhandl, ED et al : Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients : A Matched Cohort Study. Am J Kidney Dis 67 : 98-110, 2016
PubMed
2) Banshodani, M et al : Association between Dialysis Modality and Cardiovascular Diseases : A Comparison between Peritoneal Dialysis and Hemodialysis. Blood Purif 49 : 302-309, 2020
PubMed
3) 新田孝作ほか : わが国の慢性透析療法の現況 (2018年12月31日現在). 透析会誌 52 : 679-754, 2019
 
4) Chapter 11 : International Comparisons, the 2018 USRDS Annual Data Report. https://www.usrds.org/media/1738/v2_c11_intcomp_18_usrds.pdf
 
5) Robinson, BM et al : International hemodialysis patient outcomes comparisons revisited : the role of practice patterns and other factors. Clin J Am Soc Nephrol 4 : 12-17, 2009.
 
6) 新田孝作ほか : わが国の慢性透析療法の現況 (2017年12月31日現在). 透析会誌 51 : 699-766, 2018
 
7) Jung, HY et al : Dialysis modality-related disparities in sudden cardiac death : hemodialysis versus peritoneal dialysis. Kidney Res Clin Pract 38 : 490-498, 2019
PubMed
8) Sun, CY et al : A comparison of the risk of congestive heart failure-related hospitalizations in patients receiving hemodialysis and peritoneal dialysis-A retrospective propensity score-matched study. PLoS One 14 : e0223336, 2019
PubMed
9) Molnar, AV et al : Dialysis Modality and Mortality in Heart Failure : A Retrospective Study of Incident Dialysis Patients. Cardiorenal Med 10 : 452-461, 2020
 
P.146 掲載の参考文献
1) 日本透析医学会 : 慢性血液透析用バスキュラーアクセスの作製および修復に関するガイドライン. 透析会誌 44 : 855-937, 2011
 
2) Yu, ASL et al (eds) : Brenner & Rector's The Kidney. 11th edition, Elsevier, Philadelphia, 2054, 2020
 
3) 日本透析医学会 : 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌 44 : 337-425, 2011
 
4) 新田孝作ほか : わが国の慢性透析療法の現況 (2018年12月31日現在). 透析会誌 52 : 679-754, 2019
 
5) Mujais, S et al : Profiling of peritoneal ultrafiltration. Kidney Int Suppl (81) : S17-S22, 2002
PubMed
6) 丹羽利充ほか : 血液透析患者の血中に蓄積している蛋白結合性尿毒症毒素であるインドキシル硫酸に対する経口吸着剤の効果. 透析会誌 24 : 312-316, 1991
 
7) Kikuchi, K et al : Gut microbiome-derived phenyl sulfate contributes to albuminuria in diabetic kidney disease. Nat Commun 10 : 1835, 2019
PubMed
P.148 掲載の参考文献
1) Surnak, M et al : Chronic Kidney Disease and Coronary Artery Disease : JACC State-of-the-Art Review. J Am Coll Cardiol 74 : 1823-1838, 2019
 
2) Burlacu, A et al : Coronary artery disease in dialysis patients : evidence synthesis, controversies and proposed management strategies. J Nephrol 34 : 39-51, 2021
PubMed
3) Kono, K et al : Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. Kidney Int 82 : 344-351, 2012
PubMed
4) Vahed, SZ et al : Vascular Calcification : An Important Understanding in Nephrology. Vasc Health Risk Manag 16 : 167-180, 2020
 
5) Bangalore, S et al : Management of Coronary Disease in Patients with Advanced Kidney Disease. N Engl J Med 382 : 1608-1618, 2020
PubMed
P.152 掲載の参考文献
1) Ethier, J et al : Aspirin prescription and outcomes in hemodialysis patients : the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 50 : 602-611, 2007
 
2) 日本循環器学会 : 2020年JCSガイドライン フォーカスアップデート版 冠動脈疾患患者における抗血栓療法. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kimura_Nakamura.pdf (2021年1月閲覧)
 
3) Fellstrom, BC et al : Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360 : 1395-1407, 2009
PubMed
4) 日本腎臓学会 (編) : エビデンスに基づくCKD診療ガイドライン 2018, 東京医学社, 東京, 2018
 
5) Jin, J et al : Effects of Beta-Blockers on Cardiovascular Events and Mortality in Dialysis Patients : A Systematic Review and Meta-Analysis. Blood Purif 48 : 51-59, 2019
PubMed
6) Hemmelgarn, BR et al : Survival after coronary revascularization among patients with kidney disease. Circulation 110 : 1890-1895, 2004
PubMed
7) Marui, A et al : Percutaneous coronary intervention versus coronary artery bypass grafting in patients with end-stage renal disease requiring dialysis (5-year outcomes of the CREDO-Kyoto PCI/CABG Registry Cohort-2). Am J Cardiol 114 : 555-561, 2014
PubMed
8) Ueki, C et al : Off-pump technique reduces surgical mortality after elective coronary artery bypass grafting in patients with preoperative renal failure. J Thorac Cardiovasc Surg 156 : 976-983, 2018
PubMed
P.156 掲載の参考文献
1) Hickson, LJ et al : Echocardiography Criteria for Structural Heart Disease in Patients With End-Stage Renal Disease Initiating Hemodialysis. J Am Coll Cardiol 67 : 1173-1182, 2016
PubMed
2) Chawla, LS et al : Proposal for a functional classification system of heart failure in patients with end-stage renal disease : proceedings of the acute dialysis quality initiative (ADQI) XI workgroup. J Am Coll Cardiol 63 : 1246-1252, 2014
PubMed
3) 日本心エコー図学会 : 抗がん剤治療関連心筋障害の診療における心エコー図検査の手引. http://www.jse.gr.jp/onco2020.pdf
 
4) Nagueh, SF et al : Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography : An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 29 : 277-314, 2016
PubMed
5) House, AA et al : Heart failure in chronic kidney disease : conclusions from a Kidney Disease : Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 95 : 1304-1317, 2019
PubMed
6) Mahmood, U et al : Cardiac biomarkers in dialysis. AIMS Genet 4 : 1-20, 2016
PubMed
P.159 掲載の参考文献
1) 日本透析医学会 : 維持血液透析ガイドライン : 血液透析処方. 透析会誌 46 : 587-632, 2013
 
2) Inaba, M et al : Association of blood pressure with all-cause mortality and stroke in Japanese hemodialysis patients : the Japan Dialysis Outcomes and Practice Pattern Study. Hemodial Int 18 : 607-615, 2014
 
3) Chou, JA et al : Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrol Dial Transplant 33 : 149-159, 2018
PubMed
4) 日本透析医学会 : 2015年版 日本透析医学会 慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌 49 : 89-158, 2016
 
5) Lok, CE et al : KDOQI Clinical Practice Guideline for Vascular Access : 2019 Update. Am J Kidney Dis 75 : S1-S164, 2020
PubMed
6) Jukema, JW et al : Prophylactic Use of Implantable Cardioverter-Defibrillators in the Prevention of Sudden Cardiac Death in Dialysis Patients. Circulation 139 : 2628-2638, 2019
PubMed
P.162 掲載の参考文献
1) Meier-Kriesche, HU et al : Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 4 : 1662-1668, 2004
PubMed
2) Rangaswami, J et al : Cardiovascular disease in the kidney transplant recipient : epidemiology, diagnosis and management strategies. Nephrol Dial Transplant 34 : 760-773, 2019
PubMed
3) Jardine, AG : Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 18 : 379-384, 2005
PubMed
P.165 掲載の参考文献
1) Collins, AJ : Cardiovascular mortality in end-stage renal disease. Am J Med Sci 325 : 163-167, 2003
PubMed
2) Wali, RK et al : Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 45 : 1051-1560, 2005
PubMed
3) Rigatto, C et al : Long-term changes in left ventricular hypertrophy after renal transplantation. Transplantation 70 : 570-575, 2000
PubMed
4) Hawwa, N et al : Reverse Remodeling and Prognosis Following Kidney Transplantation in Contemporary Patients With Cardiac Dysfunction. J Am Coll Cardiol 66 : 1779-1787, 2015
PubMed
5) Bock, JS et al : Cardiorenal syndrome : new perspectives. Circulation 121 : 2592-2600, 2010
PubMed
6) Kidney Disease : Improving Global Outcomes (KDIGO) Transplant Work Group : KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9 (Suppl 3) : S1-S155, 2009
 

書評

最近チェックした商品履歴

Loading...